Key Update: NWCI and NBS Print E-mail
By M.E.Garza   
Thursday, 29 April 2010 08:02

NewCardio, Inc., (OTC Bulletin Board:NWCI) a cardiac diagnostic technology provider, announced today that a leading global biopharmaceutical services provider has signed a MSA, licensing NewCardio's QTinno™ software solution to enhance its delivery of fully automated cardiac safety analyses for early phase QT studies.

The CRO is expected to deploy QTinno in several clinical unit locations worldwide. In addition, NWCI announced today that the CRO has signed a services work order related to the first study using QTinno, which is scheduled to be initiated this June.

Our sources tell us that recent talks between the managment os NWCI and a large cap company that wants to inject a substantial amount of capital into the company in exchange for a partnership went very well and that "negotiations on price are underway." These types of deals always take time and patience, but it looks like everyone who has been following our investigative coverage of these events may have something to smile about soon.

"NewCardio now has agreements with three of the leading CROs in the industry," said Vincent Renz, NewCardio's President and Chief Operating Officer. "We are excited about the prospects of this latest agreement, which will result in initial study-related revenue for NewCardio. We continue to believe the transition from semi-automated to fully automated cardiac safety analysis in early phase QT studies is inevitable and accelerating, and the successful completion of our initial studies is expected to lead the market to shift to more high quality, cost effective fully automated studies in the near future. For the CRO, this agreement expands their scope of services in QT studies, enabling them to enhance delivery of high-quality cardiac safety analyses."



The Vatican Supports Stem Cell Research?

University Details Stem Cell Partnership With Vatican

Vatican, opposed to embryonic cell use, supports adult stem cell study

Some of you may have missed this news, but it appears that the Roman Catholic Church  may be the last organization you'd expect to fund stem cell research, but that's precisely what they're planning to do. Ever since the news hit the wires late last week, we've been wondering if NeoStem's (AMEX:NBS) technology is not a perfect candidate for an endorsement from the Vatican given the fact that the company's stem cell-based therapies for anti-aging initiatives meet all of the Church's requirements for funding.

In addition, the company is building a network of adult stem cell collection centers in the United States and China.

Couple this with the fact that we have been hearing that NBS has "big headline grabbing news on the way" and we can't help but continue to urge a closer look at the company. You don't want to miss this party if we hear something in the next week or two- as rumblings have it.

 

Disclosure: Long NWCI and NBS




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter